Toll Free: 1-888-928-9744

Aplastic Anemia - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aplastic Anemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2016, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1, 1 and 5 respectively.Aplastic Anemia.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Aplastic Anemia Overview 7 Therapeutics Development 8 Pipeline Products for Aplastic Anemia - Overview 8 Aplastic Anemia - Therapeutics under Development by Companies 9 Aplastic Anemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Aplastic Anemia - Products under Development by Companies 13 Aplastic Anemia - Companies Involved in Therapeutics Development 14 3SBio Inc 14 Acceleron Pharma Inc 15 Amgen Inc 16 BioLineRx Ltd 17 F. Hoffmann-La Roche Ltd 18 Gamida Cell Ltd 19 Pluristem Therapeutics Inc 20 Regen BioPharma Inc 21 Aplastic Anemia - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 Anemir - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BL-8040 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Cell Therapy for Aplastic Anemia - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CordIn - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 HemaXellerate - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 PLXR-18 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 romiplostim - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 sotatercept - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 thrombopoietin - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Aplastic Anemia - Dormant Projects 62 Aplastic Anemia - Discontinued Products 63 Aplastic Anemia - Product Development Milestones 64 Featured News & Press Releases 64 Oct 24, 2016: Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, for treatment of Bone Marrow Suppression Study 64 Sep 22, 2016: Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy 64 May 11, 2016: Regen BioPharma Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate 65 May 03, 2016: Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients 66 Jan 26, 2016: Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product 67 Dec 15, 2015: Regen BioPharma Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate 67 Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions 68 Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application 69 Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting 69 Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate 70 Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia 71 Jul 21, 2015: Regen BioPharma Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study 71 Jul 09, 2015: Regen BioPharma Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study 72 May 05, 2015: Regen BioPharma presents HemaXellerate at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC 73 Apr 22, 2015: Regen BioPharma Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial 73 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Aplastic Anemia, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Aplastic Anemia - Pipeline by 3SBio Inc, H2 2016 14 Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H2 2016 15 Aplastic Anemia - Pipeline by Amgen Inc, H2 2016 16 Aplastic Anemia - Pipeline by BioLineRx Ltd, H2 2016 17 Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 18 Aplastic Anemia - Pipeline by Gamida Cell Ltd, H2 2016 19 Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc, H2 2016 20 Aplastic Anemia - Pipeline by Regen BioPharma Inc, H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Aplastic Anemia - Dormant Projects, H2 2016 62 Aplastic Anemia - Discontinued Products, H2 2016 63



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify